Best in Biotech 19 Nov 2024
Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
Antibodies
- Latest Posts
In Depth 18 Nov 2024
What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
Best in Biotech 14 Oct 2024
Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.
In Depth 18 Sep 2024
Two targets, one solution: The rise of bispecific antibodies
Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like.
More News! 26 Jul 2024
Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies
Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.
How a microbial expression update is driving biotech innovation
Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.
ADVERTISEMENT
ADVERTISEMENT
Large molecule manufacturing: addressing challenges with strategies for success
Discover the landscape of large molecule manufacturing, exploring challenges, latest innovations, and winning strategies for success.
Best in Biotech 7 Mar 2024
6 biotech companies tackling antibiotic resistance
Discover six antibiotic companies developing novel therapies in an attempt to overcome the global issue of antibiotic resistance.
News and Trends 20 Jun 2023
Clearance for anti-tumor bispecific antibody trial
TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […]
News and Trends 16 May 2023
LabGenius looks to create molecules with huge increase in tumor killing ability
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]
News and Trends 2 May 2023
FDA fast track for Memo’s kidney transplant infection treatment
Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]
News and Trends 8 Mar 2023
Affibody and Chiesi Group to develop treatments for respiratory diseases
Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]
ADVERTISEMENT
